3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
38
Carcinoma, Renal Cell
12
Carcinoma, Non-Small-Cell Lung
12
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
8
Carcinoma, Merkel Cell
8
Uterine Cervical Neoplasms
7
Stomach Neoplasms
7
Colorectal Neoplasms
6
Carcinoma, Transitional Cell
6
Carcinoma, Hepatocellular
6
Small Cell Lung Carcinoma
5
Neoplasms
5
Kidney Neoplasms
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Esophageal Neoplasms
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Neoplasms by Histologic Type
2
Microsatellite Instability
2
Mesothelioma, Malignant
2
Mesothelioma
2
Lymphoma
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Squamous Cell
2
Interventions
cobimetinib
2
spartalizumab
1
pembrolizumab
1
osimertinib
1
glutathione pegylated liposomal doxorubicin
1
entrectinib
1
atezolizumab
1
alectinib
1
Vemurafenib
1
Trastuzumab
1
Taxes
1
Radiosurgery
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
HuMax-IL8
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
atezolizumab
×
Dermatologic
×
Clear all
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled